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1. Introduction 
 
 
1.1. Epidemiology and Pathoanatomy of Parkinson’s Disease 
The idea of neuronal loss with the progress of age was first proposed by Hodge 
in 1894 (Hodge 1894). Several studies have further investigated and confirmed 
a specific form of this phenomenon specifically in the Substania Nigra (SN) (Mann 
and Yates 1983; McGeer et al. 1988; Fearnley and Lees 1991). The death of the 
dopamine releasing neurons in the SN is then manifested in the form of 
Parkinson’s Disease (PD) (Michel, Hirsch, and Hunot 2016; Dauer and 
Przedborski 2003). James Parkinson was first to describe the disease in his 
classic “An Essay on the Shaking Palsy” (Parkinson et al. 2002) and since then, 
we have come a long way in understanding the nature and course of the disease. 
The disease is characterized by its cardinal symptoms: bradykinesia, tremor, 
rigidity and impaired postural reflexes (note that this is according to the UK 
Parkinson's Disease Society Brain Bank (UKPDSB) Clinical Diagnostic Criteria 
(Hughes et al. 1992) that may be substituted by new criteria (Postuma et al. 2015) 
that no longer include postural reflex deficits in the cardinal criteria). This work is 
based on the UKPDSB criteria. These motor symptoms are central to the 
diagnosis of PD. In addition, increased attention is given to the non-motor 
symptoms of the disease particularly in the prodromal and early stages (Postuma 
et al. 2015). 
 
Epidemiology 
PD is the second most common neurodegenerative disease after Alzheimer’s 
disease (Lau and Breteler 2006). Studies focusing on the epidemiology of PD 
have shown a prevalence rate between 5 and 346 per 100.000 persons in Europe 
(Von Campenhausen et al. 2005; Van Den Eeden 2003; Dauer and Przedborski 
2003). New calculations (Heinzel et al. 2018) suggest that the wide range of 
reported incident rates might be due to different methodologies of these studies 
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and the incident rate may be even higher than previously reported due to the 
obscure nature of the disease and its symptoms. The risk of developing PD has 
been shown to be associated with several factors such as age, gender, ethnicity 
and (other) environmental factors (Tysnes and Storstein 2017; Van Den Eeden 
2003). The risk of PD increases as age progresses, particularly after the age of 
60 years (Von Campenhausen et al. 2005; de Rijk et al. 2000; Van Den Eeden 
2003). Studies investigating the prevalence of PD found that males are more 
susceptible to the disease compared to females (Li et al. 1985; Mayeux et al. 
1995; Fall et al. 1996). Oestrogen has been suggested as neuroprotective and 
hence can lower the risk of developing PD but its role is controversial (Saunders-
Pullman 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathoanatomy 
The disease affects many different neurotransmitter systems; however, the 
dopaminergic system, especially the neurons located in the SN, show early 
degeneration during the disease course of PD. Their pathological and 
microscopic changes precede the clinical presentation up to decades (Lang 
2011; Stern, Lang, and Poewe 2012). 
 
Figure1: PD incidence by both age and gender (Van Den Eden, 
2002) 
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A sequence of changes develops in 
affected neurons. These neurons 
eventually form Lewy bodies in the 
perikarya and Lewy neurites in the 
neuronal processes. Lewy bodies 
contain abnormally phosphorylated 
neurofilaments as well as other 
components such as ubiquitin and 
alpha-synuclein (Baba et al. 1998; 
Gai, Blumbergs, and Blessing 
1995). These protein components 
lose their functions long before the 
affected neurons degenerate 
(Braak and Braak 2000). 
The cell bodies of the nigrostriatal 
neurons (located in the SN pars 
compacta (SNpc)) project mainly to 
the putamen and the loss of these 
neurons leads to the classical SNpc 
depigmentation (Dauer and 
Przedborski 2003). In contrast, the 
mesolimbic dopaminergic neurons, 
with their cell bodies neighbouring 
the SNpc in the ventral tegmental 
area (VTA), project their neurons to the caudate and are not as affected in PD. 
Hence, the dopamine transporter loss is most prominent in the putamen but less 
so in the caudate nucleus (Niznik et al. 1991; Dauer and Przedborski 2003).  
The disease starts to present itself clinically when about 80% of the putaminal 
dopamine transporter and 60% of the neurons are already lost. This degeneration 
in the neurons projected from the SN affects the functions of various brain areas 
such as the motor cortex, the limbic system and the amygdala, leading to the 
Figure 2: A. A normally pigmented Substantia 
Nigra (SN) projecting neurons from the Substantia 
Nigra pars compacta (SNpc) and ventral 
tegmental area (VTA) to the putamen and caudate 
nuclei respectively. B. In PD, neuronal loss in the 
SNpc leads to depigmentation in the SNpc while 
the VTA remains considerably intact. Therefore, 
the strength of the projection to the putamen is 
diminished, while the projection to the caudate is 
affected less. C) The pathohistology of the 
degenerated neurons containing Lewy Bodies; to 
the left those with alpha-synuclein and to the right 
those including ubiquitin (Dauer and Przedborski 
2003). 
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classical observed symptoms of PD (Braak and Braak 2000). Figure 2 provides 
histological information about these processes. 
 
1.2. Clinical Features  
For a long time, PD has been known mostly for its motor symptoms. Recently, 
more emphasis has been put on the non-motor aspects of the disease even if the 
cardinal motor symptoms maintain their importance (Postuma et al. 2015; 
Postuma et al. 2016). 
 
1.2.1. Motor Symptoms 
The understanding of the disease and its motor symptoms is still evolving and 
changing (Postuma et al. 2016; Postuma et al. 2015). There is a plethora of motor 
signs and symptoms associated with PD (Mazzoni, Shabbott, and Cortés 2012). 
The cardinal signs of PD are bradykinesia, rigidity, tremor and loss of postural 
flexibility (Gelb, Oliver, and Gilman 1999; Goetz et al. 2008; Lees, Hardy, and 
Revesz 2009; Fahn et al. 2004). Here, I do not describe these cardinal symptoms 
in detail but focus on the main motor signs and symptoms related to the work at 
hand i.e.: gait-related symptoms. 
 
Gait & Posture 
The disease has a characteristic pattern of movement particularly in the gait and 
posture domain. Posture abnormalities such as flexed posture (stooped posture), 
camptocormia (abnormal thoracolumbar flexion), antecollis (abnormal neck 
flexion of minimum 45°), Pisa syndrome (lateral flexion of more than 10° in the 
spine) and scoliosis are commonly observed in PD (Jankovic 2008; Doherty et 
al. 2011; Mazzoni, Shabbott, and Cortés 2012). During walking, the clinician can 
observe shortened and variable steps, a decrease in pace and diminished arm 
swing among other characteristics (Schaafsma et al. 2003; Morris et al. 1998). A 
more elaborate assessment of gait in PD, using advanced technology, reveals 
flat foot strikes (in extreme situations, the toe can even hit the ground before the 
heel), prolonged double limb support time, and increased step-to-step and stride-
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to-stride variability (Hughes et al. 1990; Schaafsma et al. 2003; Morris et al. 1998; 
Brauer and Morris 2010; Boonstra et al. 2008). 
 
 
 
Furthermore, a combination of motor and cognitive (discussed below) 
impairments increases the risk of falling, often during turning (Haertner et al. 
2018). Rigidity and bradykinesia have been reported to cause impairments in 
interlimb coordination in PD patients (Winogrodzka et al. 2005). Moreover, 
freezing of gait (interruption of walking sequences) have been documented as a 
common feature of PD (Jankovic 2008). 
 
Other Motor Symptoms 
PD patients often show many additional motor symptoms that vary in severity 
depending on the disease stage and medication. These symptoms include 
akinesia (delayed initiation of movement and poverty of movement), hypokinesia 
(reduced amplitude of movement), dexterity and difficulties standing up and 
Figure 3: A normal posture and gait (left) and a classical demonstration of a PD patient (right, 
adapted from the original work of James Parkinson).  
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performing motor dual tasking (DT) (Mazzoni, Shabbott, and Cortés 2012). 
Moreover, difficulties with speech, writing and swallowing are common, especially 
in advanced stages of the disease (Mazzoni, Shabbott, and Cortés 2012). 
 
1.2.2. Non-Motor Symptoms 
There is a persistent perception of PD as a dominantly motor syndrome, and that 
motor symptoms have a central role in the disease and patient’s life. Yet, more 
attention has been given recently to non-motor symptoms of PD (Postuma et al. 
2016). These symptoms are common, relevant to daily life activities and the 
quality of life (van Uem et al. 2016). Therefore, a better understanding of them 
and the effect of the treatment of choice is important. Furthermore, several non-
motor symptoms such as rapid eye movement sleep behaviour disorder (RBD) 
and hyposmia, have been shown to clinical present themselves often before any 
motor symptom is clinically observed (Poewe 2008; Postuma et al. 2012; 
Muslimovic et al. 2005). 
The non-motor symptoms of PD can be grouped into the following (Park and 
Stacy 2009; Chaudhuri, Healy, and Schapira 2006): 
 
Cognitive Symptoms 
These symptoms are presented in more detail as they are specifically relevant 
for the topic of this work. How to observe cognitive symptoms in PD depends on 
the nature of the symptom itself, disease severity and the method used to asses 
them. A study reported that up to 80% of PD patients develop dementia 
(Chaudhuri and Schapira 2009). Other studies show deficits in the frontal 
executive functions in about 30% of PD patients (Lees and Smith 1983; Park and 
Stacy 2009). Further cognitive symptoms in PD include: visuospatial and 
visuoperceptual deficits, apathy, impaired set shifting, poor problem solving 
abilities, and attention inflexibility (Chaudhuri and Schapira 2009; Chaudhuri, 
Healy, and Schapira 2006; Park and Stacy 2009; Hobert et al. 2011). Comparable 
to motor symptoms, these symptoms may or may not fluctuate. Furthermore, a 
relevant body of literature shows impairment in DT abilities and prioritization 
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strategies in PD patients (Brauer and Morris 2010; Hackney and Earhart 2010; 
Yogev-Seligmann et al. 2010; Yogev-Seligmann, Hausdorff, and Giladi 2012). 
Cognitive functions are relevantly associated with quality of gait (Yogev-
Seligmann, Hausdorff, and Giladi 2008; van Iersel et al. 2008; Hobert et al. 2017) 
and especially with falls (Verghese et al. 2008; Holtzer, Wang, and Verghese 
2012). Not surprisingly, gait quality can predict some forms of cognitive deficits 
(Morris et al. 2017). 
More specifically, Lord and colleagues (Lord et al. 2010) have shown that 
executive functions, motor functions and attention, all contribute to gait velocity 
and gait interference in PD patients. Other studies have shown that DT is a 
challenging cognitive setting that negatively affects gait, particularly gait 
variability (Hausdorff, Balash, and Giladi 2003). Executive dysfunction 
exacerbates this negative effect of DT on gait variability, making it even more 
challenging and riskier (Yogev et al. 2005). Taken together, cognitive 
impairments in PD are heavily involved in gait dysfunctions and worsen the 
challenging effect of DT on gait parameters. As PD medication influences both, 
motor and cognitive deficits in PD. Hence, the understanding of the interplay 
between cognition and gait in PD under Off- and On- medication conditions is 
paramount. 
 
Neuropsychiatric Symptoms 
Depression (occurs in approximately 40% of patients), psychosis, apathy, fatigue 
and anxiety (occur in up to 45% of patients, respectively) are neuropsychiatric 
symptoms that are more common in PD than in the age-matched general 
population (Siciliano et al. 2018). Many patients also report visual and auditory 
hallucinations (Park and Stacy 2009). Some of these symptoms are induced or 
at least triggered by dopaminergic medication ((Swainson et al. 2000; Chaudhuri 
and Schapira 2009), see also below). There might be a possible overlap between 
some of the cognitive and neuropsychiatric deficits in PD (Chaudhuri and 
Schapira 2009). 
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Sleeping 
In PD, disturbances in sleep are reported in 60-90% of patients (Park and Stacy 
2009). That includes problems falling asleep (earliest and most frequent), 
maintaining quality sleeping and sleepiness during the day, as well as RBD 
(Sveinbjornsdottir 2016). 
 
Autonomic Symptoms 
Autonomic disturbances reported in PD include constipation, nausea, urogenital 
difficulties, sexual dysfunction, orthostatic hypotension and excessive sweating 
(Sveinbjornsdottir 2016).  
 
Other Non-motor Symptoms 
Various other symptoms present themselves in PD with varying prevalence. For 
example, sensory symptoms such as pain, hyposmia and paraesthesia are often 
observed clinically or reported by patients (Park and Stacy 2009; Chaudhuri and 
Schapira 2009). Other symptoms include blurred vision, seborrhoea, diplopia and 
weight loss (Chaudhuri and Schapira 2009). 
 
1.3. Straight Walking and Turning in Parkinson’s Disease 
Several gait phases show changes throughout the course of the disease. Straight 
walking, the most studied type of walking, can provide important information 
about pace, variability and rhythmicity of gait in PD patients (Galna, Lord, and 
Rochester 2013; Lord et al. 2013). 
Turning, another phase of walking, is also deteriorated in PD and associated with 
increased risk of freezing and falling among others (Bloem et al. 2001; Cheng et 
al. 2014). The complexity of turning as an activity requires complex coupling of 
posture and gait, continuous movement of one’s centre of gravity as well as inter-
limb coordination (Cheng et al. 2014; Mellone et al. 2016; Haertner et al. 2018). 
Turning is challenging particularly for PD patients, who often suffer from postural 
instability, because it requires changing direction in an ongoing movement. This 
movement includes a disequilibrium state during a single limb stance, something 
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that is difficult for patients with postural instability (Song et al. 2012; Stack and 
Ashburn 2008). 
It is important to distinguish between straight walking and turning as they are –at 
least partly- planned and executed differently in the brain, in particular in older 
adults and PD patients (Stack, Ashburn, and Jupp 2006; Stack and Ashburn 
2008; Crenna et al. 2007). Seeking safety and maintaining balance while turning, 
PD patients develop specific strategies to turn (Stack, Ashburn, and Jupp 2006). 
 
There are several ways of assessing gait. Home assessment offers real-life 
information, that accurately reflects gait characteristics (Lipsitz et al. 1991; Lord 
et al. 2011; Stack, Ashburn, and Jupp 2006). However, assessing gait in artificial 
settings is easier to perform, and thus, much more widely used as it provides 
more standardized information, parameters and a chance for more variety of 
assessments such as walking backwards and using cues (Baker, Rochester, and 
Nieuwboer 2008; Hackney and Earhart 2010). An important, relatively new 
method of investigating gait in PD patients is through unobtrusive IMUs (Maetzler 
et al. 2013). Such a method provides objective and accurate information about 
gait characteristics, which might not be observed by the clinician because they 
are too subtle or they take place even before a diagnosis is reached (Mirelman, 
Gurevich, et al. 2011). 
 
1.4. Treatment 
 
1.4.1.  Dopaminergic Treatment 
Dopamine medication has been established as the most suitable and common 
medication for PD symptoms (Connolly and Lang 2014). While it is shown to 
improve mostly the more distal motor symptoms (Lees, Hardy, and Revesz 2009), 
it has a limited effect on other symptoms, in particular on gait domains such as 
gait variability (Lord et al. 2011; Bloem et al. 1996). It also has a limited effect on 
turning. Previous studies have shown that dopaminergic medication can improve 
peak velocity during turning as well as step duration but no other parameters such 
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as axial velocity (Hong and Earhart 2010; McNeely and Earhart 2011; Curtze et 
al. 2015). 
Dopaminergic medication has a mixed effect on cognitive functions improving 
some of them and negatively affecting some others (Cools et al. 2001; Cools et 
al. 2003; Cools et al. 2007). For instance, dopaminergic medication has been 
shown to improve cognitive flexibility and verbal fluency (Gotham, Brown, and 
Marsden 1988; Cools et al. 2003), and to deteriorate some forms of learning 
(Cools et al. 2007). 
 
1.4.2. Side Effects of Dopaminergic Treatment 
Albeit generally well tolerated, possible short term complications of dopaminergic 
medication include hallucinations, nausea, vomiting and impulse control 
disorders (Connolly and Lang 2014). Prolonged administration of dopaminergic 
medication is often associated with the occurrence of dyskinesias and motor 
fluctuations. The prevalence of such complications is about 50% in patients who 
receive dopaminergic medication for more than five years (Fahn 2000). They are 
mainly managed by (more) continuous treatment strategies (see below). These 
side effects in addition to the inefficacy of dopaminergic medications in several 
aspects of PD lead to a need for alternative therapies and interventions for PD 
such are those discussed in the following section. 
 
1.4.3. Other Lines of Treatment 
Deep Brain Stimulation (DBS) and Other Continuous Treatments 
In DBS, high frequency stimulation mainly of the subthalamic nucleus (STN; other 
areas are currently investigated) “normalizes” functionality typically disturbed in 
PD (Benabid et al. 2009). Since its first application in PD in 1993, it has shown to 
significantly improve tremor, rigidity, dyskinesia and motor fluctuation, among 
other symptoms. This treatment generally enables clinicians to substantially 
reduce dopaminergic medication and to increase health-related quality of life 
(HrQoL) (Benabid et al. 2009; Deuschl et al. 2006). DBS has a beneficial effect 
also in the postural instability gait disability (PIGD) PD subtype, especially in the 
first year after surgery (Fasano, Daniele, and Albanese 2012). This suggests that 
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this treatment has beneficial effects on gait and balance. Nonetheless, George et 
al. have found that DBS alone has no relevant effect on postural instability and 
gait disability in PD (George et al. 2010). They found a beneficial effect in the 
combination of DBS with Levodopa in the globus pallidus internus. 
 
Other continuous treatment options are pumps (subcutaneous, apomorphine; via 
duodenal application, levodopa infusion (Timpka, Mundt-Petersen, and Odin 
2016). Patients with cognitive dysfunction and those who want to omit surgical 
treatment are potential candidates. 
 
Physiotherapy 
Physiotherapy has been shown to improve gait, particularly gait velocity 
(Tomlinson et al. 2013). There are many strategies and methods for 
physiotherapy training such as cueing, strength and balance training, relaxation 
and massage, stretching, aerobic straining and trunk strength exercises 
(Nieuwboer et al. 2007; Keus et al. 2007; Goodwin et al. 2008). Some studies 
have shown positive results from alternative treatment options such as Tai Chi 
training, which has been shown to improve postural stability, emotional well-
being, Tinetti’s Falls Efficacy scale and some parts of the PD Questionnaire-39, 
related to daily life and communication (Li et al. 2012; Nocera et al. 2013). 
Furthermore, several studies have recommended exergaming for PD 
rehabilitation by showing significant benefit of the intervention on cognitive and 
motor levels (Barry, Galna, and Rochester 2014; Herz et al. 2013). 
 
Recently Developed Treatments 
Recently, stem cell therapy has made way as an option for treating motor and 
non-motor PD symptoms (Pantcheva et al. 2015). Another new treatment option 
is focused ultrasound subthalamotomy, particularly for patients with asymmetric 
PD (Martínez-Fernández et al. 2018) as the method is currently applied only at 
one side of the brain. 
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1.5. Dual Tasking 
1.5.1. Anatomical and Functional Aspects of Dual Tasking 
DT is the state of performing two tasks simultaneously and its paradigms have 
been used to investigate executive function (Adcock et al. 2000). There have 
been efforts to locate DT in the brain. However, it is more likely that executive 
functions are mediated by diverse systems, anatomically and functionally that 
vary depending on the processes involved (Adcock et al. 2000). Although the 
frontal lobe, parietal lobe and premotor cortex have been reported to be activated 
during DT, activity is probably specific for the task performed in that particular 
study (Wu and Hallett 2008). Moreover, the same study has shown that DT cost 
(DTC, deterioration in the performance of one or both tasks compared to the 
performance of the task under ST condition) is not dependent on the overlap 
between the brain areas involved in executing the two tasks (Wu and Hallett 
2008). 
 
1.5.2. Dual Tasking in Parkinson’s Disease 
Many studies had shown that DT has a negative effect on both primary (in this 
case, gait) and secondary tasks (O’Shea, Morris, and Iansek 2002; Yogev-
Seligmann et al. 2010; Yogev-Seligmann, Hausdorff, and Giladi 2012). Such a 
negative effect is even more prominent in PD patients because of their 
deteriorated cognitive and mental state (Hausdorff, Balash, and Giladi 2003; 
Yogev-Seligmann, Hausdorff, and Giladi 2008; Hobert et al. 2011). Moreover, DT 
is very common in daily life. One can even argue that we are constantly in DT 
mode when awake. There are conflicting theories about whether the nature of the 
secondary task plays a role in the DTC or not (O’Shea, Morris, and Iansek 2002; 
Galletly and Brauer 2005). Hence, it is of great interest to investigate how DT 
affects straight walking and turning with secondary tasks of different nature. Most 
of the studies investigating the effect of medication on walking and turning are 
performed in single tasking (ST) conditions. To my knowledge, this is the first 
study to investigate turning during DT in PD patients both in Off- and On-
medication conditions. 
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1.6. Unified Parkinson’s Disease Rating Scale (UPDRS) 
For the past few decades, the UPDRS (Unified PD Rating Scale) has been the 
method of choice for evaluating PD. The scale is in principle a clinician’s 
assessment of specific clinical aspects of a patient. In 2007 the UPDRS 
underwent a revision with the Movement disorders society (MDS) (Goetz et al. 
2008). A task force modified the scale to the current MDS-UPDRS version that 
includes the following parts: 
 
(I) Non-motor aspects of daily life (13 items) 
(II) Motor aspects of daily life (13 items) 
(III) Motor examination (18 items) 
(IV) Motor complications (six items) 
 
A score between zero and four is typically given to each item of the scale as 
follows: 0= Normal, 1= Slight, 2= Mild, 3= Moderate and 4= Severe impairment. 
The shortcomings of the UPDRS, even in its modified version, includes its large 
subjectivity depending on the clinician’s experience and opinion. Therefore, 
interrater variability is a common reliability issue (Richards et al. 1994). 
1.7. Assessment of Movement in Parkinson’s Disease using Inertial 
Measurement Units 
Recently, technology has provided several alternatives for assessing movement 
disorders in general and PD in particular (Sánchez-Ferro et al. 2016). Using a 
camera system, force plate or Inertial Measurement Units (IMUs) is becoming 
preferable, or at least complementary, to using the traditional UPDRS. These 
methods offer objectivity and better accuracy than the naked eye. IMUs, 
especially, are unobtrusive, economical and usable in different environments 
(Maetzler et al. 2013; Sánchez-Ferro et al. 2016; Maetzler and Rochester 2015). 
There are many studies that show the advances as well as the challenges in the 
field of movement assessment in PD using IMUs (Maetzler et al. 2013; Horak, 
King, and Mancini 2015). 
There are several brands and types of IMUs (Figure 4) (Sánchez-Ferro et al. 
2016; Laurie King 2013; Donath et al. 2016). All of them include a 3D 
 14 
accelerometer, measuring the acceleration of the sensor when fixed on a moving 
body in the three orthogonal axes (x, y, z). IMUs also include a 3D gyroscope; a 
device used to measure the rotation around the three axes. From the data of the 
gyroscope and the accelerometer combined, one could calculate the orientation 
of the IMU. A magnetometer is also often included in the IMU devices, but their 
use is limited because of the disturbances from magnetic fields in the 
surroundings. 
 
 
Figure 4: Photograph of a typical Inertial Measurement Unit (IMU), the OPAL device (Mobility 
Lab®, APDM, Oregon, USA). The OPAL contains a 3D accelerometer, a 3D gyroscope and a 
magnetometer (Source: Mobility Lab user guide, https://bit.ly/2TPXWLy). 
 
 
 
1.8. Study hypotheses 
This study investigates the effect of dopaminergic medication on gait and turning 
in PD under cognitively challenging conditions using IMUs. 
My main hypothesis is that dopaminergic medication improves particular aspects 
(e.g. velocity) of gait and turning in PD but has no significant effect on other 
domains of these movements (e.g. gait variability). 
Furthermore, I hypothesize that the cognitively challenging conditions (in this 
case DT) diminish the influence the medication has on gait during the ST 
conditions. 
Testing these hypotheses is important for a more objective assessment of the 
effect of dopaminergic medication on gait in PD.  
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This study is partially explorative, given the novelty of investigating turning 
parameters in ST and DT during Off- and On-medication conditions. 
This work should add to the discussion on the relationship between gait and 
cognition, especially in PD patients. 
The questions that will be explored are as follows: 
- How effective is dopaminergic medication at improving straight walking 
and turning in mild-moderate PD patients? 
- Is the same effect observed under challenging conditions i.e., DT 
conditions? 
- What gait parameters (and domains) are responsive to the dopaminergic 
medication? 
- How does dopaminergic medication affect two cognitive tasks of different 
nature and with different demands? 
  
 
 
2. Materials and Methods 
 
2.1. Original Study 
The participants included in this study were part of a study investigating an 
inflammatory subtype of PD (Yilmaz et al. 2018). Patients were recruited from the 
ward and outpatients’ clinic of the neurology department, University Hospital 
Tübingen. Moreover, some patients were recruited from a private neurology 
practice in Stuttgart. The inclusion criteria were age above 40 years and fulfilling 
the UKBBS criteria for idiopathic PD (Gibb and Lees 1988). For the substudy 
relevant for this document (discussed below), additional inclusion criteria were 
being younger than 80 years and being physically independent (no walking aid 
necessary). 
All of the included PD patients were at stage 2 or 3 on the Hoehn & Yahr (H&Y) 
scale (Hoehn and Yahr 1967). Exclusion criteria were the use of central nervous 
system medication (except dopaminergic drugs and antidepressants) or suffering 
from depression (more than 19 points on the Beck’s Depression Inventory (BDI-
II)) or other neurodegenerative diseases. 
 
The overall study (Yilmaz et al. 2018) included 145 PD patients from Tübingen 
(another cohort of 90 PD patients was included from Toronto, Canada). The 
patients recruited in Tübingen were asked to take part in this substudy, which 
made an assessment in both, Off- and On-medication necessary. 
The study design included several motor and cognitive tests, patients’ 
biomaterials investigations as well as collecting the history of chronic diseases 
and falls during the previous two years. The ethical committee of the medical 
faculty of the University of Tübingen approved the study (No. 715/2011BO2). All 
participants provided written informed consent prior to the assessments. 
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2.2. Study Design and Population 
From the entire study (Yilmaz et al. 2018) which included 145 PD patients, 120 
patients agreed to take part in this substudy. The Movement Disorders Society 
(MDS) revised UPDRS, part III (MDS-UPDRS III) was used to assess the severity 
of symptoms and effect of medication (Goetz et al. 2008) (see also below).  
Of the 124 patients, 66 patients performed the assessment in both Off- and On-
medication conditions by the time of this analysis and were hence included in the 
analysis. 
Off-medication condition was defined and achieved when the patient skipped 
their medication overnight until they performed the assessment the following day 
(no medication for about 9-12 hours). On-medication conditions were defined 
according to each participant feeling “a good On-phase”, typically achieved 45-
90 minutes after taking the usual dopaminergic medication. Figure 5 
demonstrates the course of measurement. 
 
Figure 5: Flow chart of the assessments. Patients performed the same protocol during Off- and 
On-medication conditions with 45-90 minutes’ interval for the medication to reach a “good On 
phase”. IMUs, inertial Measurement Units. 
 
Seven patients could not perform all the iWALK assessments (used in this work) 
as they felt tired or opted to not complete the protocol. I excluded patients who 
needed walking aid during the assessment (N=4) and Patients who performed 
the assessment incorrectly according to the movement capture system 
algorithms (N=8) were also excluded. Three patients were excluded because 
they performed the DT serial subtraction (SS) in steps of three (e.g.: 391, 388, 
385) instead of seven. I then included only patients with at least two points 
improvement in the MDS-UPDRS III in the On-medication compared to the Off-
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medication condition for the analysis, as this is widely considered the minimum 
clinically relevant improvement (MCRI). The MCRI indicates that the PD patient 
has indeed benefited from taking the medication (Schrag et al. 2006; Shulman et 
al. 2010). This led to exclusion of five more patients from the final analysis. Thus, 
39 patients were included in the final dataset. 
 
2.3. Clinical, Cognitive and Psychometric Assessments 
Several tests were performed to evaluate the neurological, cognitive and 
psychological state of the patients. These tests are as follows: 
 
MDS-UPDRS III 
In this study, a Movement Disorder Society approved specialist performed the 
third part of the MDS-UPDRS on patients once during each the Off- and the On-
medication conditions. 
The MDS-UPDRS III consists of 18 items investigating several motor aspects, 
including gait and posture. The items of the MDS-UPDRS III are as follows:  
Speech, facial expression, rigidity of neck and extremities, finger tapping, hand 
movements, pronation/supination, toe tapping, leg agility, arising from chair, gait, 
freezing of gait, postural stability, posture, global spontaneity of movement, 
postural tremor of the hands, kinetic tremor of hands, rest tremor amplitude, 
constancy of rest tremor. 
 
The highest (and worst) possible score is 132 points. An exact validated 
classification of PD symptoms severity based on the MDS-UPDRS III score is still 
lacking. However, clinical experience suggests that moderate PD patients would 
usually have a score of 20-30 points, and severe PD patients would have a score 
of about 50 points. 
 
Mini-Mental State Examination (MMSE)  
The MMSE (Folstein, Folstein, and McHugh 1975) is used to screen for cognitive 
deficits and track the course of Alzheimer’s and other diseases with an element 
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of dementia. The test evaluates the cognitive state of the participant in terms of: 
orientation, attention, computational abilities, memory, language comprehension 
and related skills. 
The highest possible (best) score of the MMSE test is 30 points. A score below 
27 indicates a cognitive restriction, a score below 24 points indicates mild 
dementia and a score below 10 points indicates severe dementia (Folstein, 
Folstein, and McHugh 1975). 
 
Trail Making Test (TMT) 
The TMT (Reitan 1958) is a neuropsychological test commonly used for 
assessment of divided attention, visuomotor coordination, and executive 
functions such as working memory and cognitive flexibility. The test consists of 
two parts, A and B. Part A assesses mainly motor speed. The participant is asked 
to connect dots numbered from 1 to 25 in an ascending order. The examiner 
records the time needed using a stopwatch. Part B assesses mainly cognitive 
flexibility and alternating attention (Drane et al. 2002). The participant is asked to 
connect the dots numbered 1-13 and A-L alternatively (1-A-2-B-3-C). The 
examiner draws the participant’s attention if they make an error, which then must 
be corrected at the expense of the time. The overall TMT performance can be 
influenced by age, educational level and motivation among other factors (Lezak 
1995). 
Delta TMT test (B-A) is considered to best reflect “pure cognitive efficiency” 
(Drane et al. 2002). 
 
BDI-II 
The BDI-II (Beck et al. 1996) is a standardized psychometric test used to detect 
and evaluate the severity of depressive symptoms. The test includes 21 
questions about sadness, un-satisfaction, anxiety about the future, guilt, self-
loathing, suicidal thoughts, irritability, social insulation, decisiveness, fatigue, 
body perception, appetite, weight, libido, and hypochondria. Each question can 
be answered on a scale from 0 (no limitation) to 3 (most severe limitation) totalling 
63 possible points. The scores are interpreted as follows: 
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0-9: minimal depression; 10-18: mild depression; 19-29: moderate depression; 
30-63: severe depression (Beck, Steer, and Carbin 1988). 
 
2.4. Tasks 
2.4.1. Gait Assessments 
For gait assessment, participants performed the following tests: 
 
- Instrumented timed up & go (iTUG) test: In this test the participants 
started from a sitting position, stood up, walked for seven meters, made a 
turn to the left (or right), and walked back and sat down again. In this study 
protocol, the test was performed once starting with the left foot, walking 7 
meters, making a left turn and once with the right foot, again walking 7 
meters and making a right turn. A third iTUG was performed at self-
selected pace over 3 meters. The patients could choose their starting foot 
and direction of turning during the third iTUG.  
 
- Instrumented sway (iSWAY) test: Participants stood in a semi-tandem 
stance (left foot forward) on a foam pad for 30 seconds once with closed 
eyes and once with open eyes. Another variation of the test was also 
performed; the participant stood on the floor for 30 seconds with a wooden 
leg separator and arms crossed on the chest, once with closed eyes and 
once with the eyes open. 
 
- Functional reach test: Participants stood with their right side to the wall, 
without leaning on it, right arm stretched forward as far as possible, body 
leaned forward as far as possible. They were asked to hold that position 
for 15 seconds before slowly going back to their starting position. The arm 
reach is marked on a sheet on the wall before and after leaning forward. 
The difference between the two markers is called the functional reach. This 
test gives insight into a participant’s balance abilities and postural stability 
(Hasmann et al. 2014). 
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- Five-chair-rise test: Starting from a sitting position, participants stood up 
and sat down five times without depending on their hands (Whitney et al. 
2005). Participants were also instructed to fully stretch their knees during 
standing and to lean back during sitting. This test was performed once in 
a convenient pace and once in a fast pace. It provides data on postural 
transitions, muscle power of the lower extremities and coordination. 
 
- Instrumented stand and walk (iSAW) test: In this test the participant 
stood still for 30 seconds with the hands relaxed next to the trunk. 
Participant then walked for seven meters, made a turn before walking back 
to the start line where they stood again facing the opposite direction of 
their starting position. This test was performed once by starting the walk 
with the left foot, turning left at the seven-meter mark, and once with the 
right foot, turning right. This test provides data on balance, step initiation 
and anticipatory postural adjustments (APAs). 
 
- Instrumented long walk (iWALK) test (Mancini 2011): Participants 
walked for one full minute up and down a well-lit 2m-wide 20m-long 
hallway. This assessment thus includes straight walking and turning 
episodes (Figure 6). Participants did not receive instructions on the foot 
they should use to start the walk or in which direction they should turn. 
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The test was performed in four conditions: 
- ST, fast pace walking. 
- ST, normal pace walking. 
- DT, fast pace walking + checking boxes (CB).  
- DT, fast pace walking + SS.  
 
The iWALK test is the movement assessment used in this analysis. It provides 
data on gait and turning parameters, which I analysed here. 
 
2.4.2. Secondary Cognitive Tasks 
The Checking Boxes (CB) task is a cognitive task with a substantial motor 
component. Based on the study protocol of Hobert an colleagues (Hobert et al. 
2011), participants checked 32 empty boxes on a sheet, while standing, in ST 
condition. Participants were instructed to always check the boxes in the same 
direction (top down, left to right). 
The Serial Subtraction (SS) task is a series of 7-steps subtractions. During ST, 
participants performed the task as a series of ten subtractions, starting from the 
number 406, while standing, by saying the numbers out loud, and as fast as they 
could. When the test had to be repeated for any reason, participants were given 
another three-digit number (396). This task is complex and considered cognitively 
Figure 6: The iWalk assessment. Source: Mobility Lab user guide (version 22nd March 2016, 
https://bit.ly/2TPXWLy, Mobility Lab® APDM). 
Turn 
walk for 20 meters 
 
 
Start/Turn 
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demanding (O’Shea, Morris, and Iansek 2002; Shumway-Cook, Brauer, and 
Woollacott 2000). For some participants, the SS was too complex with the 7-
steps calculation. They were then given an easier task of subtracting 3-steps from 
a 3-digit number. These participants were, as mentioned in the methods, 
excluded from the analysis for incompatibility with the rest of the cohort. 
 
During DT, participants were asked to perform the secondary task as fast as 
possible, with the explicit instruction “walk as fast as possible without running and 
check the boxes / calculate SS also as fast as possible” to avoid creating a biased 
prioritisation of one task over the other. 
 
2.5. Movement Capture 
Participants wore eight inertial measurement units (IMUs) named OPAL from the 
Mobility Lab system (Mobility Lab®, APDM, Oregon, USA) (Mancini 2011) (Figure 
6). The Mobility Lab system also includes an access point, a docking station and 
the software for data acquisition, analysis and export of results. Components of 
the Mobility Lab system are shown in Figure 7. 
 
 
 
Figure 7: The Mobility Lab system includes an access point, a docking station, IMUs and a 
software with validated algorithms (Mancini 2011). 
 
The access point streams the data from the IMUs directly to the laptop during the 
assessment as long as the IMUs are within a range of 20m from the access point. 
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When the IMUs are out of range, data are 
stored on the internal storage and then 
streamed to the access point as soon as 
they are in range again. 
The docking station is used to calibrate the 
IMUs before each measurement session, 
to charge the IMUs batteries and to turn 
them off at the end of the session. 
When starting a measurement, all used 
IMUs synchronize together through the 
software and the data are streamed online 
to the access point using WiFi channels. 
 
These IMUs were distributed on the body 
as follows (see also Figure 8): one on the 
trunk (chest), one on the lumbar area, one 
on each wrist, one on each shin and one 
on each foot. They were all fixed on the 
body parts using adjustable elastic 
washable belts. The iWALK test uses data 
from the arms, waist and feet IMUs. 
The Mobility Lab system includes 
algorithms for the analysis of different 
movements and activities. Merging data 
from the accelerometer, gyroscope and magnetometer, the algorithm uses the so 
called “quaternion”, a mathematical system applied to the mechanics in three-
dimensions (Mancini 2011). 
 
2.6. Data Extraction and Analysis 
Based on previous work on gait domains, I focused my analysis on gait 
parameters that belong to relevant and independent gait domains (Lord et al. 
2013). These parameters were: gait velocity, stride duration, double limb support 
Figure 8: Self-made visualisation of the 
positioning of eight IMUs on the patient’s 
body. All IMUs had the same orientation 
and were synchronized together. 
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time, stride duration variability, double limb support variability and stride length 
asymmetry. Stride duration variability and double limb support variability were 
calculated from the standard deviation [SD] of the first 30 steps of straight 
walking. Previous work has shown the reliability of this approach (Galna, Lord, 
and Rochester 2013).  
 
The above-mentioned parameters are defined as follows: 
 
• Gait velocity: the distance in meters covered per second [m/s]. 
• Step frequency: the average number of steps performed per minute 
[steps/min]. 
• Double limb support time: the percentage of time spent with both feet on 
the floor from the total gait cycle time [%]. 
• Stride length asymmetry: the average difference in the length of strides 
performed with the left and those performed with the right leg [SD]. 
• Stride duration variability: the stride to stride fluctuation in duration [SD]. 
• Double limb support time variability: the fluctuation in double limb support 
duration from one gait cycle to the other [SD]. 
 
For the turning phase, turning is defined by the system’s developers as any 
rotation of 45° or more around the Y axis with a duration of 0.5s-10s (Pearson et 
al. 2013). I selected turning parameters that have been established by previous 
studies as independent and clinically relevant parameters (Stack and Ashburn 
2008; Hong and Earhart 2010). Turning parameters were defined as follows: 
 
• Total duration: the time in seconds required in average to perform a turn 
of 180° [s]. 
• Step duration: the average time in seconds required to perform one step 
during turning [s]. 
• Number of steps: the average number of steps a participant performs 
during the turn [steps/turn]. 
• Peak velocity: the maximum velocity of turning around the Y axis [°/s]. 
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• Last step duration: the average duration of the last step of walking before 
turning starts [s]. 
 
Data extraction and calculation of variability parameters and preparation for 
statistical analysis were performed using a script written by the author using 
Matlab 8.4 (MathWorks, Natick, Massachusetts). The Matlab functions used in 
this step are provided as Supplementary Material 1 and 2 at the end of this work. 
 
2.7. Data Analysis and Statistics 
Since ST CB was calculated as the time needed to check 32 boxes as fast 
possible, while DT was performed as checking as many boxes as possible in one 
minute. I normalized the performance using the following equation: 
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Similarly, for SS, ST was performed by recording the time needed to perform ten 
consecutive subtractions as fast as possible. In DT SS, participants performed 
as many subtractions as they could in one minute. I normalized the performance 
using the following equation: 
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Paired t-test was used to compare between the Off- and On-medication 
conditions. Mann-Whitney-Wilcoxon (MWW) test was performed as an alternative 
when the data were not normally distributed. I tested for the normal distribution 
of the data using the Shapiro-Wilk test (Field 2013). I set the significance level at 
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p<0.05. I did not correct for multiple testing due to the partially exploratory nature 
of this study. Data analysis was performed using JMP software 11.1.1 (SAS 
institute, 2014). 
  
 
3. Results 
 
 
Results of the cognitive testing (MMSE) show that the participants did not suffer 
from significant cognitive impairment. Participants scored on average 29 points. 
BDI-II score of my participants was 7 points on average.  
 
3.1. Effect of Medication on MDS-UPDRS III Score 
As defined in the exclusion criteria, the dopaminergic medication improved the 
MDS-UPDRS III score of all participants included in the analysis by minimum two 
points. The average MDS-UPDRS III score of all participants decreased 
significantly (nine points on average) during the On-medications compared to the 
Off-medication condition (p<0.0001) (Table 1). 
 
 
Table 1: Demographic data of participants in Off- and On-medication conditions. 
Data are presented in mean and standard deviation (SD). Data comparison was performed 
using paired t-test. Significance level was set at p<0.05. 
BDI-II, Beck Depression Inventory; F, Female; H&Y, Hoehn and Yahr, MDS-UPDRS III, motor 
part of the Movement Disorders Society Revised-Unified Parkinson’s Disease Rating Scale; 
M, male; MMSE, Mini-Mental State Examination. 
 Off-medication On-medication p-value 
Age [years] 65.2 (6.9)  
Gender M:31; F:8  
MMSE (0-30) - 29 (2)  
BDI-II (0-63) - 7 (6)  
MDS-UPDRS III (0-132) 30 (9) 21 (7) < 0.0001 
H&Y (0-5) 
35 patients in stage 2 
4 patients in stage 3 
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3.2. Effect of Medication on Straight Walking during ST and DT 
For straight walking during ST, gait velocity was significantly higher during the 
On-medication condition than during Off-mediation condition (p=0.03). No 
significant differences were observed in other measured gait parameters during 
ST. Step frequency was comparable between Off- and On-medication (129 vs 
128 steps/m; p=0.25). Double limb support time was 16.3% and 16.2% of gait 
cycle time (p=0.78) under Off- and On-medication conditions, respectively. Stride 
length asymmetry was recorded at 1.60m/s and 1.50m/s during Off- and On-
medication conditions (pMWW=0.26). Stride duration variability was 0.03s (p=0.78) 
during both Off- and On-medication conditions. Double limb support variability 
was 2.2% and 2.4% (p=0.76), during Off- and On-medication respectively. A 
visual overview of the parameter measured is provided in Figure 9. 
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Figure 9: Straight walking parameters in Off (red)- and On-medication (blue) conditions during 
ST and DT. Comparisons performed using paired t-test when the data were normally distributed 
and Mann Whitney U test when the data were non-normally distributed. 
%: percentage of gait cycle time; *: significant difference (p<0.05); CB: checking boxes; m: meter; 
s: seconds; SS: serial subtraction. 
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For straight walking during DT (CB), no significant effect of medication on any 
of the assessed gait parameters could be seen (Table 2). Gait velocity was 
recorded at average 1.35 m/s in On-medication compared to 1.37 m/s during Off-
medication (p=0.18). Step frequency was observed at 139 steps/min in On-
medication compared to 138 steps/min during Off-medication conditions 
(p=0.49). Double limb support time was 19.4% of gait cycle time during On-
medication compared to 19.7% during Off-medication (p=0.78). Stride length 
symmetry was 1.50 [SD] during On-medication compared to 1.60 [SD] during Off-
medication (p=0.78). Stride time variability was 0.04 [SD] in Off- and On-
medication conditions during DT conditions with both secondary tasks (p=0.76). 
Double limb support variability was 2.4 [SD] during On-medication compared to 
2.2 [SD] during the Off-medication (pMWW=0.27). 
 
Straight walking parameters during DT of SS did not show any significant 
change under the influence of dopaminergic medication. Gait velocity during On-
medication conditions was 1.37 m/s compared to 1.35 m/s during Off-medication 
(p=0.27). Step frequency was averaged at 155 step/min during both Off- and On-
medication conditions (pMWW=0.96). Double limb support time was recorded at 
19.7% of gait cycle time in On-medication conditions compared to 19.1% during 
Off-medication conditions. Stride length asymmetry during On-medication 
conditions was recorded at 1.55 [SD] compared to 1.66 [SD] during the Off-
medication conditions (pMWW=0.34). Stride duration variability was 0.04 [SD] 
during both conditions (pMWW=0.90). Double limb support time variability (2.4 [SD], 
pMWW=0.69) was comparable between Off- and On-medication conditions. 
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Table 2: Performance of straight walking during Off- and On-medication conditions in ST 
and DT. 
Data presented in mean and (Standard deviation, SD). Paired t-test was used for normally 
distributed data. Mann-Whitney U test (italic) was used for non-normally distributed data. 
Significance level was p<0.05. DT, dual tasking; ST, single tasking. 
Parameter Off-medication On-medication p-value 
Straight walking (ST)    
Gait velocity [m/s] 1.58 (0.16) 1.61 (0.16) 0.03 
Step frequency [steps/min] 128 (9) 129 (13) 0.25 
Double limb support time [%] 16.3 (4.3) 16.2 (4.6) 0.78 
Stride length asymmetry [SD] 1.60 (0.54) 1.50 (0.53) 0.26 
Stride duration variability [SD] 0.03 (0.01) 0.03 (0.01) 0.78 
Double limb support variability [SD] 2.2 (0.7) 2.4 (1.0) 0.27 
 
Straight walking during CB (DT) 
Gait velocity [m/s] 1.37 (0.17) 1.35 (0.19) 0.18 
Step frequency [steps/min] 117 (11) 118 (13) 0.49 
Double limb support time [%] 19.7 (4.5) 19.4 (4.9) 0.56 
Stride length asymmetry [SD] 1.87 (0.60) 1.79 (0.66) 0.35 
Stride duration variability [SD] 0.04 (0.02) 0.04 (0.02) 0.76 
Double limb support variability [SD] 2.8 (1.2) 2.5 (1.1) 0.22 
 
Straight walking during SS (DT) 
Gait velocity [m/s] 1.35 (0.21) 1.37 (0.18) 0.27 
Step frequency [steps/min] 115 (11) 115 (11) 0.96 
Double limb support time [%] 19.1 (4.6) 19.7 (4.2) 0.77 
Stride length asymmetry [SD] 1.64 (0.59) 1.55 (0.56) 0.34 
Stride duration variability [SD] 0.04 (0.03) 0.04 (0.04) 0.90 
Double limb support variability [SD] 2.3 (1.6) 2.3 (1.4) 0.69 
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3.3. Effect of Medication on Turning Parameters during ST and DT 
For turning parameters during ST, step duration (pMWW=0.048) was shorter 
(0.53s and 0.51s in Off- and On-medication conditions), and peak velocity 
(p=0.04) was higher during On-medication (173°/s) condition compared to Off-
medication condition (164°/s). 
In the remaining parameters, no significant change was recorded between the 
different medication conditions. The following parameters are still mentioned: The 
total duration of turns on average decreased by 0.2s during On-medication 
conditions (pMWW=0.18). The number of steps performed per turn was 6 steps in 
Off-medication and 5 steps in On-medication (pMWW=0.23). The duration of the 
last step before turning remained virtually unchanged at 0.48s in both Off- and 
On-medication conditions (p=0.18). 
During the DT CB assessment, no significant influence of medication on gait 
could be observed. The following parameters are still mentioned: The mean total 
duration of the turns increased by 0.4s under the dopaminergic medication 
influence (pMWW=0.68). Step duration decreased by 0.3s (pMWW=0.30). The 
number of steps per turn was 7 during both Off- and On-medication conditions 
(pMWW=0.90). Peak velocity of turning was recorded at 129°/s during On-
medication compared to 130°/s during Off-medication conditions (p=0.84). Last 
step duration was 0.53s during both Off- and On-medication conditions (p=0.49). 
Details are presented in Figure 10. 
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Figure 10: Turning parameters in Off (red)- and On-medication (blue) conditions during ST and DT. 
Comparisons were performed using paired t-test when the data were normally distributed and Mann 
Whitney U when the data were non-normally distributed. 
*, significant difference (p<0.05); CB, checking boxes; SS, serial subtraction. 
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In the DT SS assessments, no significant changes in turning parameters could 
be observed. The duration of turn was 2.8s in Off-medication conditions and 2.7s 
in On-medication conditions (pMWW=0.41). Step duration during turns was 0.60s 
during Off-medication conditions, compared to 0.62s during On-medication 
(pMWW=0.41). Participants performed on average 6 steps/turn in the Off-
medication conditions and 5 steps/turn in On- medication conditions (pMWW=0.09). 
Peak velocity of turning was 147°/s during Off-medication and 154°/s in On-
medication conditions (p=0.31). The duration of the last step before turning was 
0.53s during Off-medication and 0.54s during On-medication (p=0.63). 
 
Table 3: Performances of turning during Off- and On-medication conditions in ST and DT. 
Data presented in mean and (Standard Deviation, SD). P-values are of paired t-test when data is 
in normal distribution and Mann-Whitney U (italic) when they are not. Significance level was 
p<0.05. CB, checking boxes; DT, dual tasking; SS, serial subtraction; ST, single tasking.  
Parameter Off-medication On-medication p-value 
Turning (ST)    
Total duration [s] 2.4 (1.1) 2.2 (0.5) 0.18 
Step duration [s] 0.53 (0.05) 0.51 (0.05) 0.048 
Number of steps [steps/turn] 6 (1) 5 (1) 0.23 
Peak velocity [°/s] 164 (34) 173 (37) 0.04 
Last step duration [s] 0.48 (0.04) 0.48 (0.04) 0.18 
 
Turning during CB (DT) 
   
Total duration [s] 3.3 (1.0) 3.7 (1.5) 0.68 
Step duration [s] 0.66 (0.32) 0.63 (0.19) 0.30 
Number of steps [steps/turn] 7 (2) 7 (2) 0.90 
Peak velocity [°/s] 130 (32) 129 (35) 0.84 
Last step duration [s] 0.53 (0.06) 0.53 (0.05) 0.49 
 
Turning during SS (DT) 
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Total duration [s] 2.8 (1.1) 2.7 (0.9) 0.41 
Step duration [s] 0.60 (0.09) 0.62 (0.20) 0.41 
Number of steps [steps/turn] 6 (2) 5 (1) 0.09 
Peak velocity [°/s] 147 (42) 154 (40) 0.31 
Last step duration [s] 0.53 (0.06) 0.54 (0.08) 0.63 
 
 
3.4. Effect of Medication on Secondary Cognitive Tasks 
The speed of CB was significantly higher during On-medication compared to Off-
medication condition. 
During ST, participants checked 89 and 98 box/min during Off- and On-
medication (p=0.04), respectively. During DT, participants performed 60 and 65 
box/min in Off- and On-medication (p=0.04). Details on CB performance are 
presented in Table 4 and in Figure 11. 
 37 
 
Figure 11: Secondary tasks performance in Off (orange)- and On-medication (blue) conditions 
during single and dual tasking. *, significant difference (p<0.05). Comparisons performed using 
paired t-test. 
CB, checking boxes; min, minute; SS, serial subtraction; sub, subtraction. 
 
 
The SS speed, during ST, participants performed 27 and 31 subtractions/min in 
Off- and On-medication, respectively (p=0.51). During DT, they performed 21 
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and 22 subtractions/min during Off- and On-medication conditions, respectively 
(p=0.85) (Table 4, Figure 11). 
 
Table 4: Performances of secondary tasks during Off- and On-medication conditions in 
ST and DT. 
Values are presented with mean and (Standard Deviation, SD). P-values are from paired t-test 
and Mann-Whitney U (italic). Significance level was at p<0.05. CB, checking boxes; DT, dual 
tasking; SS, serial subtraction; ST, single tasking; sub., subtraction. 
 
Parameter Off-medication On-medication p-value 
Secondary Tasks    
Speed of CB ST [box/min] 89 (16) 98 (16) 0.04 
Speed of CB DT [box/min] 60 (16) 65 (14) 0.04 
 
Speed of SS ST [sub./min] 
 
27 (16) 
 
31 (18) 
 
0.51 
Speed of SS DT [sub./min] 21 (11) 22 (11) 0.85 
  
 
 
4. Discussion 
 
In this work, I investigated the effect of dopaminergic medication on straight 
walking, turning and two cognitive tasks during ST and DT conditions. 
Dopaminergic medication has been the treatment of choice for PD for the past 
few decades (Connolly and Lang 2014). Albeit the deteriorating effect on some 
PD symptoms, it has been shown to improve other motor symptoms as well as 
several cognitive functions (Fahn et al. 2004; Cools et al. 2007; Cools et al. 2003; 
Cools et al. 2001; Swainson et al. 2000). For example, it is well established that 
the following aspects respond positively to dopaminergic treatment: tremors, 
akinesia, rigidity (Pogarell et al. 2002; Schrag et al. 1999), and cognitive flexibility 
(Cools et al. 2003). However, it is less well investigated, which effect 
dopaminergic medication has on straight walking and turning, especially under 
DT conditions, as these aspects are difficult to evaluate with the “naked” clinical 
eye. Due to advances in technology, we now have the means to objectively 
assess the effect and benefits of dopaminergic medication on such features and 
functions. 
 
I hypothesized that dopaminergic medication will have a positive effect on some 
gait parameters during straight walking, e.g. gait velocity, stride length and swing 
velocity (Blin et al. 1991), but no significant effect on some other parameters, e.g. 
stride duration and gait variability, which has been reported to be resistant to 
dopaminergic medication (Blin et al. 1991; Lord et al. 2011). 
I also hypothesized that the medication will have positive effects on some turning 
parameters such as the peak velocity and total duration of turning (Curtze et al. 
2015), but no significant effect on other parameters such as the number of steps 
needed to turn and step duration (Curtze et al. 2015; Hong and Earhart 2010; 
McNeely and Earhart 2011). 
I tested that effect during ST and DT, for gait parameters during straight walking 
and turning phases, hypothesising a more limited effect of medication during DT. 
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I also aimed to explore the effect of medication on two different types of cognitive 
tasks in PD during ST and DT conditions. These two tasks were CB, a secondary 
cognitive task with a rather motor nature and SS, a secondary task that demands 
complex executive functions processes. 
 
For these purposes, I used a recent technology to assess movement in PD, i.e. 
IMUs (Sánchez-Ferro et al. 2016; Horak, King, and Mancini 2015). IMUs, are 
economic, unobtrusive and can be used in the lab or home environments. As the 
use is uncomplicated, it is an assessment with high potential also for peripheral 
hospitals and regions with low income and limited access to health systems. They 
provide a plethora of data parameters in various relevant gait domains and other 
types of human movement. 
 
My study showed that dopaminergic medication has a limited effect on straight 
walking (improved only gait velocity) and turning (improved step duration and 
peak velocity), and that this beneficial effect was only observed during ST. During 
DT, I didn’t find considerable benefits. I also found that dopaminergic medication 
improved the motor aspects of cognition associated with motor planning and fine 
motor functions but didn’t improve the complex task associated with cognitive 
flexibility. 
 
4.1. Gait and Turning in Parkinson’s Disease 
Gait is an important part of daily life activities, and is more complex than originally 
thought (Hausdorff et al. 2005). Gait deficits in PD are common, and often 
presented by significantly declined velocity, small and fast steps, diminished arm 
swing, deviated posture and a remarkable axial rigidity. These deficits result in 
high-risk gait patterns, leading to e.g. falls (Schaafsma et al. 2003; M. Morris et 
al. 1998). Moreover, PD patients’ physical independence and social life are often 
significantly affected by deteriorated gait velocity and increased postural 
instability (van Uem et al. 2016). 
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Turning is basically a part of walking but has recently been investigated more 
often independently from (straight) walking because of its importance for daily 
activities and relation to falls (Cheng et al. 2014; Mellone et al. 2016). It is also 
very probable that turning is planned and executed at least in part independently 
from straight walking networks in the human brain (Cheng et al. 2014; Mellone et 
al. 2016). Moreover, turning is often impaired in PD patients, and linked to higher 
risk of falling and freezing (Cheng et al. 2014; Haertner et al. 2018; El-Gohary et 
al. 2014). PD patients seem to develop different strategies for safe well-balanced 
turning (Stack, Ashburn, and Jupp 2006; McNeely and Earhart 2011). 
Taken together, safe walking and turning are paramount to PD patients. Selecting 
the ideal treatment is hence crucial in tackling gait and turning deficits in PD. As 
the effects of potential treatment (also beyond the treatment presented here) on 
straight walking and turning may differ, the following discussion will address the 
findings of straight walking and turning separately. 
 
4.2. The Effect of Dopaminergic Medication on Straight Walking 
during Single and Dual Tasking 
A main finding of this study is the limited effect of dopaminergic medication on 
straight walking during ST and even more during DT. The improvement of gait 
velocity by medication during ST is consistent with previous work (Baltadjieva et 
al. 2006; Lord et al. 2011). Previous studies also showed that medication 
improved some gait domains only during ST but had no positive effect during the 
more daily-relevant DT conditions (Silsupadol et al. 2006; Hackney and Earhart 
2010). Although the medication may thus have only a limited effect, it may still be 
relevant for single patients, e.g. when the main issue is to walk from one place to 
another.  
 
My results also confirm previous studies suggesting that step frequency and 
double limb support variability do not improve by dopaminergic medication during 
ST (Almeida et al. 2007; Schaafsma et al. 2003).  
Almeida et al compared the gait of 19 and 23 idiopathic PD patients in Off- and 
On-medication conditions, respectively. They also measured 30 participants as 
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control group. Data from this study were extracted from a 14-ft pressure-sensitive 
carpet, which is designed to detect foot pressure (e.g., during walking). Results 
of this study show that double limb support variability was higher in the PD Off-
medication group than in the control group but was not different from the On-
medication state. It must however be taken into consideration that the study 
included two separate groups measured in Off- and On-medication and did not 
include intraindividual comparisons in its design. This could limit the conclusions 
drawn from the findings regarding the causality of medication on gait differences. 
 
Furthermore, as in my study, others have shown that stride duration variability is 
not significantly influenced by dopaminergic medication (Lord et al. 2011; 
Hausdorff, Balash, and Giladi 2003). This means that an improvement in time 
domain-related gait variability in general is not expected from dopaminergic 
medication during ST or DT conditions. This indicates that even though all these 
gait domains are affected by PD (Almeida et al. 2007; Schaafsma et al. 2003), 
they are probably not relevantly triggered by deficits in the dopaminergic system 
and consequently not responsive to dopaminergic medication. Although it is 
impossible to draw a definite conclusion at this point, it is possible that at least 
some gait parameters that deteriorate in PD are mostly affected by (deterioration 
of) neurotransmitter systems associated with, e.g., cognitive deficits. This 
assumption is supported by the increase in gait variability during DT conditions, 
which are cognitively challenging. It is also supported by previous work 
(Hausdorff, Balash, and Giladi 2003) showing that gait variability deteriorates 
under cognitively challenging conditions. In their study, Hausdorff and colleagues 
investigated 10 idiopathic PD patients during their On-medication condition. 
These participants walked a 20m-hallway in ST normal pace settings, and again 
in DT conditions while performing the SS task (similar to the SS task in this work). 
The main findings of their study were the much larger (154%) stride time 
variability and what they described as a “hesitant gait” (describe here what they 
mean with the term) during DT compared to ST. The authors concluded that DT 
conditions exacerbates gait variability and further impairs stable walking in PD. 
They recommended interventions for PD patients with focus on limiting 
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distractions and DT during walking, in hope to maintain a more stable, safe gait. 
In other words, they recommended a “more cognitive” approach to improve gait 
variability rather than using medication (or motor training). 
 
Is gait velocity alone enough? 
Gait velocity is an important parameter for the independent performance of daily 
life activities in both older adults and PD patients. It is often used as a predictor 
of survival and adverse effects such as falling (Studenski et al. 2011; Montero-
Odasso et al. 2005). An improved gait velocity can help patients maintain 
independency and a better social life. Hence, it is possible that the lone 
improvement in gait velocity from the dopaminergic medication is satisfying for 
many patients. 
On the other hand, it is possible that improving gait velocity without improving 
further parameters of gait that are important for dynamic stability (such as 
postural control and variability) (Henderson et al. 2016; Boonstra et al. 2008) may 
lead to dangerous situations per se as the higher velocity is not compensated by 
the postural system. It may also give a false sense of safety for PD patients and 
thus lead to a higher risk of falling. Moreover, dopaminergic medication often has 
side effects (motor, cognitive and emotional), and the right balance between the 
benefits (coming from improved mobility) and disadvantages has to be 
determined in every single case. 
 
Taking together, PD patients can benefit from dopaminergic medication 
concerning gait velocity under ST conditions, but it should always be discussed 
and decided on an individual basis whether this gain of velocity is relevant for the 
patient given the risks and side effects discussed above. 
 
4.3. The Effect of Medication on Turning during Single and Dual 
Tasking 
Turning is an important phase of gait and is linked to a higher risk of freezing and 
falling (Cheng et al. 2014; McNeely and Earhart 2011). Turning requires complex 
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planning, locomotion and postural control. A relatively limited number of studies 
in PD focused on the turning phase of walking even though it has a significant 
role clinically and in patients’ daily life (Hong and Earhart 2010; Curtze et al. 2015; 
McNeely and Earhart 2011). Even fewer studies investigated the effect of 
medication on turning parameters in PD. To my knowledge, this is the first study 
to investigate turning in PD during both ST and DT, and the first to show the effect 
of medication on turning during DT conditions. 
My findings show that dopaminergic medication has a limited positive effect on 
turning during ST. It only improved step duration and peak velocity of turning. 
These findings are in line with previous studies showing improvement in these 
parameters during ST conditions (Hong and Earhart 2010; Curtze et al. 2015). A 
previous study (Curtze et al. 2015) presents a ranking of responsiveness of 
turning parameters to Levodopa (under ST conditions). In this study, the authors 
investigated gait, balance, posture and turning in 104 patients with a protocol of 
three iSAW assessments (30s standing still followed by 7m straight walking and 
a 180° turn). The difference in that study protocol, compared to this study, may 
make straight walking results incomparable. The turning results in the above-
mentioned study and this are, however, comparable and support one another. 
Similar to their work, I found peak velocity of turning to be most responsive to the 
dopaminergic medication. However, I found step duration during turning to be the 
only additional sensitive parameter to dopaminergic medication. Mean step 
duration was ranked least responsive in Curzte’s work. It’s possible that this 
difference in results is due to the differences in the two protocols. My study 
included multiple turns per assessment, each performed after 20m of walking, 
while they included one turn per assessment after a 7m walk only. 
I included PD patients in a mild-moderate disease stage, and the other study 
(Curtze et al. 2015) also partly included patients that were more severely affected. 
It is thus also possible that this difference has an effect on the respective results, 
and, consequently, patients in different PD stages may respond to dopaminergic 
medication differently in terms of turning parameters. If that is the case, it might 
be useful to explore if responsiveness of turning parameters, e.g. step duration, 
to dopaminergic medication can serve as a progression marker in PD. 
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Previous studies showed that older individuals, in particular PD patients, develop 
their own strategies to ensure a safer turning (Stack, Ashburn, and Jupp 2006). 
Examples of strategies adopted by PD patients for safe turning are spinning in 
place, making more steps over a longer curvature to turn and splitting a turn into 
smaller parts of movements with pauses in between (Stack, Ashburn, and Jupp 
2006). It would be interesting to compare the medication effect on these 
strategies, which is beyond the scope of the work presented here and should be 
investigated in future studies. 
 
Regarding how turning parameters respond to dopaminergic medication during 
DT conditions, none of the parameters investigated here responded to the 
medication. I could not find, to the date of composing this work, any studies that 
can confirm, support or contradict these findings. As discussed above, it’s 
possible that the complexity of a concurrent cognitive task may limit the benefits 
of the dopaminergic medication. We have also established that turning is a 
complex movement that requires planning and complicated dynamics. These two 
factors combined might be the reason turning during DT don’t benefit at all from 
the dopaminergic medication. 
 
4.4. The Effect of Dopaminergic Medication on the MDS-UPDRS III 
Score 
 
An improvement in the MDS-UPDRS III score (Goetz et al. 2008) between Off- 
and On-medication was given –per definition- in all 39 patients selected for my 
analysis. Previous studies suggest that a minimum of two points improvement 
must be observed in order to consider it clinically significant, a difference termed 
“minimum clinically relevant improvement” (MCRI) (Schrag et al. 2006; Shulman 
et al. 2010). I recognize that the medication had a positive effect on the motor 
functions of the participants, but this was obviously not seen in (and thus, not due 
to) straight walking and turning parameters assessed here during ST and during 
DT. It is thus probable that the improvement seen in the MDS-UPDRS III is mostly 
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due to improvements of the fine motor functions in the upper limbs. This argument 
is supported by the observed improvement in the CB speed as it has a fine motor 
component. 
 
4.5. How Does Dopaminergic Medication Affect Cognition? 
Cognitive impairment is a common symptom of PD. It can be in the form of deficits 
in components such as memory, attention, and motor planning. The challenging 
DT conditions magnify these deficits, and hence, increase the risk of e.g. falling. 
In this study, dopaminergic medication improved the cognitive functions with 
mainly a motor component (CB) but not the more complex task related to 
executive functions (SS). This effect was observed during both ST and DT. 
 
The disparity of effectiveness on different cognitive tasks may be due to different 
reasons. First, SS might be too complex and cognitively challenging to improve 
with dopaminergic medication, in contrast to CB, the cognitively easier task to 
perform. Secondly, it is possible that an improvement in the movement, not 
cognition itself, is what led to the improved secondary task of CB. Thirdly, it can 
be argued that most patients perceive SS as more difficult than CB, hence, riskier 
and more dangerous. Thus, they focus on safe walking when performing such a 
“dangerous” task. However, the medication did not improve SS even during ST, 
when no risks were imposed, which speaks against this possibility. Fourthly, it is 
well possible that the more complex secondary task depends more on non-
dopaminergic pathways and networks, such as the cholinergic system. In fact, 
recent literature shows that cholinesterase inhibitors have a beneficial effect on 
mobility that is associated with cognitive load. For example, (Chung et al. 2010) 
showed that postural stability improved in 23 fallers with PD, who were given 
cholinesterase inhibitors. That led to a 40% decrease in their falling frequency 
compared to placebo treatment. The authors concluded that cholinergic 
medication may have improved attention in these patients which led to less falls. 
This assumption also argues for the central role of cognitive functions in PD 
patients’ movement. Moreover, the association between cholinergic pathways 
and postural stability has also been shown in older adults in recent work (Arnold 
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et al. 2018). Whether the influence is directly motor or rather through improving 
cognition (as Chung et al suggest) is a question that should be further 
investigated. 
Another recent work (Henderson et al. 2016) found that rivastigmine (an 
acetylcholinesterase inhibitor) improved gait variability during normal walking and 
simple DT in PD patients compared to those who were given placebo. However, 
gait variability did not improve during “difficult” DT. Based on that, one can argue 
that firstly, the difficulty of the secondary task (cognitive challenge) does affect 
the motor benefits gained from the medication and may block them. Secondly, 
PD patients can be advised to avoid DT conditions only when the secondary task 
is “too difficult” for the medication to be effective. 
 
Taken together, these observations indicate that cognitive tasks with simple 
aspects are to a certain degree responsive to dopaminergic medication and can 
be targeted with such treatments options and the complexity of some other 
cognitive tasks may block  -or may not be responsive to- (the effect of) 
dopaminergic medication as shown by (Henderson et al. 2016). 
I mentioned above the possibility that the dopaminergic medication had no 
positive effect on the cognitive abilities and the improvement in CB speed was 
caused purely by the improvement in the fine motor functions as shown in the 
MDS-UPDRS-III score. This interpretation is in line with the work showing that 
motor impairments e.g.: rigidity and bradykinesia in the upper limbs are indeed 
responsive to dopaminergic medication, independent of whether they are 
performed alone or simultaneously with another task (Schrag et al. 1999). 
Furthermore, this finding is consistent with the high direct correlation of the 
Purdue pegboard test scores and the nigrostriatal dopaminergic deficit as 
measured with Fluorodopa positron emission tomography (Vingerhoets et al. 
1997). 
 
As a consequence, the effect of dopaminergic medication on cognition as 
observed in this study investigating straight and curved walking as well as the 
body of literature investigating this aspect, motivates to use treatment strategies 
for PD that do not only focus on one mechanism and a specific drug. Combining 
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medication with cognitive therapy and most probably also physio- and 
occupational therapy seems most promising also for PD patients with deficits in 
gait and turning. In the following, I will elaborate on some treatment options, which 
I consider potentially useful for these patients. However, it should be noted that 
direct evidence supporting these treatment options is currently not fully sufficient. 
 
- Treadmill Training 
In their review, (Mehrholz et al. 2015) analysed 18 treatment studies in PD using 
treadmill training. Results of these studies indicate that treadmill training 
improves gait velocity and step length. While that is directly beneficial to PD 
patients by improving their quality of life, an improved gait velocity is also a 
predictor of a better life expectancy (Montero-Odasso et al. 2005). The 
mechanics of treadmill walking could also increase gait regularity. It is thus 
probable that the same PD patients tested in this study would benefit from 
treadmill training, at least concerning deficits during straight walking under ST 
conditions. 
In regard to DT, Mirelman et al. (Mirelman, Maidan, et al. 2011) showed that four 
weeks of treadmill combined with virtual reality training improved DT gait velocity 
and decreased gait variability in 20 PD patients. In a more recent and larger work 
(Mirelman et al. 2016), the authors showed that treadmill training in addition to 
virtual reality training (i.e.: in DT training) benefited postural control and led to 
less falls and risk of falling compared to treadmill training alone. 
These findings together strongly suggest that treadmill training benefits ST and 
DT walking in PD patients and that DT treadmill training is even more beneficial 
than ST training. Moreover, the improvements in gait variability, which is resistant 
to dopaminergic medication, argue for combining this type of training with the 
medication to target more dopaminergic-resistant gait parameters. 
Regarding treadmill training to improve turning in PD, it’s difficult to target and 
train turning, because the treadmill is made for straight walking by design. 
Nonetheless, Hong and Earhart (Hong and Earhart 2008) did show that treadmill 
training can improve freezing of gait symptoms during turning in PD patients. 
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Based on this finding, it is reasonable to hypothesize that turning per se might 
also benefit from treadmill training. 
 
- Exergaming Training 
Recent studies have shown benefits of exergaming on movement in PD patients 
(Barry, Galna, and Rochester 2014; Mirelman et al. 2016). Stride length improved 
in PD patients who received exergaming training. Moreover, this improvement 
was observed during DT conditions. This implies an improvement also in the 
cognitive aspects of the disease. 
The convenience of exergaming, being available to patients at home and for 
unlimited time is an advantage to consider in the application of such methods 
discussed here. 
 
- Tai Chi Training 
It has been shown that Tai Chi has positive effects on postural stability, ST gait 
velocity and step length in PD patients (Li et al. 2012). This effect was also better 
than some other investigated methods such as stretching and strength training. 
Another study investigating 31 participants (Wayne et al. 2015) found that six 
months of Tai Chi training improved DT gait velocity and gait variability. The study 
also showed that Tai Chi experts had a lower (better) DT gait variability than novel 
Tai Chi participants. It is interesting to note that the benefits of Tai Chi training 
are more prominent during DT than ST. The reason for this may be that Tai Chi 
includes both motor and cognitive aspects. This assumption is indirectly 
supported by another study which found an effect of Tai Chi on emotional well-
being score, digits backwords test and fear of falling (as part of the Tinetti Falls 
Efficacy Scale) (Nocera et al. 2013). This advantage (improving gait during DT) 
may nominate Tai Chi practice as a fitting training method particularly for PD 
patients who typically show difficulties with DT. 
 
- Cueing 
Another method of improving gait, e.g. by preventing freezing, in PD is the use of 
cues. Cues can be auditory, visual or tactile. 
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A recent work by Ghai et al. (Ghai et al. 2018) reviewed 50 studies investigating 
the effect of rhythmic auditory cues on gait in PD. Taken together, these studies 
show that auditory cueing training improves gait velocity, cadence, step length 
and gait variability in PD patients during straight walking. Sessions of 20-45 
minutes of training are recommended for patients, three to five times a week 
(Lohnes and Earhart 2011). 
Other studies, such as (Fietzek et al. 2014), show the positive effect of different 
forms of cueing (visual and tactile) on straight walking in PD, improving velocity 
and step length, and decreasing freezing episodes. 
Regarding turning, one study (Nieuwboer et al. 2009) investigated the short-term 
effect of different cueing modalities on the duration of turns. The intervention 
performed in 153 PD patients increased the mean speed of turning. They, 
however, suggest that the effect on functionality needs to be further studied. 
Another study (Spildooren et al. 2012) found that cueing training decreased 
freezing of gait episodes during turning. These benefits disappeared in a very 
short time after the cueing stopped, which however should not lead us to 
conclude that the treatment is not effective (medication has also effects over 
limited periods of time if not continuously given). 
 
- Cognitive Training 
As shown in my results and in the literature discussed above, cognition has an 
important influence on gait. More specifically, one study (Holtzer, Wang, and 
Verghese 2012) showed that executive attention is related with gait velocity and 
step length during both ST and DT. The cognitive state and abilities of PD patients 
affect the quality of their gait. For example, deteriorated executive functions are 
associated with wrong prioritisation strategies in PD, resulting in a higher risk of 
e.g. falling (van Iersel et al. 2008). It has also been proven that cognitively 
challenging conditions (e.g. DT) lead to slower gait and higher risk of falling and 
freezing (Beauchet et al. 2009). 
Hence, cognitive training could be very beneficial for some PD patients. 
Improving attention, attention flexibility and executive functions will most likely 
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improve postural stability and safety, particularly during turning (Petzinger et al. 
2013; Geritz, Maetzler, and Schlenstedt 2018). 
In their work, Walton and colleagues (Walton et al. 2014) showed that targeted 
cognitive training can improve executive processes and thus decrease the risk 
and occurrence of freezing of gait in PD. One study (Yogev-Seligmann et al. 
2012) proposed a training program for PD patients to improve their DT walking. 
They performed four walking assessments: one ST and three DT with the 
following secondary tasks (SS, information processes and open-ended complex 
questions). They then received four weeks of cognitive training that was 
specifically designed to improve the SS and information processes. After the 
training, participants performed the walking assessments again. Gait velocity 
improved in all patients in all DT conditions, including the condition that did not 
receive specific training (open-ended complex questions). Gait (stride time) 
variability also improved with training. The improvements in gait in these patients 
were still observable four weeks after the training. The study however included 
only seven PD patients. Another study (Milman et al. 2014) included a larger 
cohort (18 PD patients) and a longer training period (12 weeks). Patients were 
asked to play certain computer games designed to improve executive function 
and attention, for 30 minutes, three times a week for three months. The TUG 
performance in these patients was recorded before and after the training 
program. In this study, as in the one mentioned above, gait velocity and variability 
improved. In addition, turning speed and turning duration also improved during 
the TUG assessments. 
What we learn from these studies is that cognitive training in different forms 
improves several aspects of gait and turning in PD patients during ST and DT. I 
could not find studies specifically examining the effects of cognitive training on 
DT turning. Therefore, future work should tackle this point. However, given the 
established benefits on cognitive and motor symptoms as well as freezing in PD, 
it is likely that DT turning also benefits from cognitive training. 
 
Taken together, gait velocity has been shown to improve by medication and 
several other methods of intervention such as treadmill training, cueing and Tai 
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Chi. In addition, the methods discussed above have the capacity to improve 
various aspects of PD. It is thus most likely that a multifaceted treatment plan is 
the most promising and effective approach to treatment of straight walking and 
turning deficits in PD. However, especially the effects of the above-discussed 
methods on DT performance, which is most relevant for daily life, has to be 
investigated in much more detail. 
An additional point to consider while creating a treatment plan, is the long-term 
benefits of a method. Cueing for example, as shown in some studies above, failed 
to create a benefit for PD patients on the long term, which may be a disadvantage 
especially for patients with low motivation and retention. On the other hand, 
cognitive training benefits were still observable weeks after the end of treatment.  
 
For many years, almost all PD patients were treated solely by neurologists or by 
general practitioners. In recent years, interdisciplinary frameworks for treating PD 
(and similar diseases) have been adopted in many health care systems (Van Der 
Eijk et al. 2013; Giladi et al. 2014). In these frameworks, teams of specialized 
healthcare professionals communicate and organize the treatment plans, training 
and daily activities of the patients. For instance, the neurologist handles the 
medications and the general orchestration of the treatment plan. The 
physiotherapist and occupational therapists build and execute a plan for physical 
and occupational training while nurses specialized in PD can address medical 
issues seen in PD patients when they visit them in the home environment. The 
neuropsychologists contribute by providing cognitive assessment and training to 
PD patients. 
This interdisciplinary approach includes several strategies that have been 
mentioned above and provide PD patients with a better chance to cope with the 
disease. The practical application of this interdisciplinary framework is already 
being implemented in several places in Germany’s leading hospitals and 
spreading to be a norm in Europe (Van Der Eijk et al. 2013; Bloem and Munneke 
2014).  
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4.6. The Use of Inertial Measurement Units to Assess Parkinson’s 
Disease 
Using IMUs, we could quantify and compare detailed aspects of walking and 
turning. Relevant parameters such as stride duration variability, double limb 
support time variability, peak velocity of turning, are practically impossible to 
quantify by the naked eye. This study adds to the increasing evidence of the 
importance of using advanced technology such as IMUs to assess movement in 
PD and other diseases (Sánchez-Ferro et al. 2016). 
There have been efforts to further exploit the objectivity and accuracy of IMUs to 
even create a gait quality scale replacing the motor part of UPDRS (Klucken et 
al. 2013). Although these efforts might be premature, it is likely that the future of 
assessing PD will eventually include such technology as a standard assessment 
tool (Hansen, Sanchez-Ferro, and Maetzler 2018). 
There are several types of technologies to quantify movement. Motion capture 
camera systems, pressure mats, and IMUs have all been extensively investigated 
and used mainly in research settings. The advantages IMUs hold over other 
options are their economic and unobtrusive nature and foremost, their 
applicability in almost any environment, including at home. It is expected that 
patients will soon be able to export their own data and have insights into their 
motor functions or the treatment efficacy on their own (Hansen, Sanchez-Ferro, 
and Maetzler 2018). 
 
4.7. Limitations and Future Work 
A limitation of this study is the relatively narrow window of patients’ selection in 
terms of disease stage (mild to moderate PD). This work should thus be 
interpreted with caution, especially before generalising its findings to other 
disease stages. Another limitation is the assessment of cognitive tasks using a 
stopwatch, which is not as objective and granular as more sophisticated 
evaluation systems (such as integrated smartphone applications). It would also 
be interesting to explore more parameters of the cognitive tasks such as the 
accuracy of SS, not only speed. My work, however, provides an important insight 
into the effect of dopaminergic medication on different walking phases during DT. 
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Moreover, this work fittingly combines several motor, cognitive and clinical 
aspects of the disease. This encourages future studies to explore these aspects 
and deficits of PD and highlights how they affect each other. 
Future work can include further analysis of parameters from the postural stability 
domain. Whether used independently or combined with gait (i.e. PIGD complex), 
it should provide useful insights into the effect of the dopaminergic medication on 
the gait domain as well. It would also be interesting to know if certain types of 
treatment are more beneficial for patients in different environments (e.g., at 
home), which can influence the execution of certain movements. 
Further analysis can also compare in more depth the effect of different types of 
cognitive tasks (here CB and SS) on straight walking and turning during Off- and 
On-medication conditions especially from a cognitive perspective. 
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5. Conclusion 
 
Dopaminergic medication, the most common treatment choice in PD, has a 
limited effect on straight walking and turning during ST. Namely, it improves gait 
velocity during straight walking, and improves step duration and peak velocity 
parameters of turning. Furthermore, it has no significant influence on these 
activities during the more daily-relevant DT conditions. The medication seems to 
have a mixed effect on cognition, improving the speed of cognitive tasks with 
substantial motor component but not more complex cognitive tasks using 
executive functions. 
 
From these observations, I suggest that a more multifaceted and multidisciplinary 
treatment strategy for PD could be more effective than drug treatment alone. This 
strategy can include, e.g., medication (also beyond dopaminergic treatment, e.g., 
choline esterase inhibitors), cognitive therapy, physio- and occupational therapy. 
Until this multifaceted and trans-disciplinary treatment is becoming a reality 
country-wide, patients should be reminded to prioritize safe walking, particularly 
during DT, where the medication is not significantly beneficial. 
 
Lastly, as shown here, wearable technology enables a more granular and an 
objective assessment of PD treatment compared to other methods such as the 
clinical eye. In the future, many other questions regarding PD can be investigated 
using this method. 
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6. Summary 
 
Parkinson’s disease (PD) is a neurodegenerative disease that leads to a 
continuous deterioration in the motor, cognitive and behavioural functions of the 
brain. The degeneration of the dopamine-releasing neurons in the basal ganglia 
throughout the course of the disease can be compensated, at least to some 
extent, by dopaminergic medication. 
Dopaminergic medication has various effects on different aspects of PD. On one 
hand, it improves several motor and cognitive functions such as distal movement, 
cognitive flexibility and attention switching. On the other hand, it has no positive 
effect on others, such as some aspects of gait and turning. It might even have a 
negative effect on some of the cognitive processes. In regard to straight walking 
and turning, two common phases of our daily walking routine that are particularly 
interesting in PD patients, dopaminergic medication has been shown to improve 
some gait domains e.g. velocity; but does not seem to have a relevant impact on 
other gait domains such as variability and rhythmicity. Moreover, most of the 
studies investigating gait in PD are performed during single tasking (ST) 
conditions. It is thus important and daily-life relevant to study gait during dual 
tasking (DT) because we are constantly performing at least two tasks if not more 
during our normal lives. 
 
In this study, I investigated the effect of dopaminergic medication on straight 
walking and turning in PD patients during ST and DT. During DT I used two 
secondary tasks: the CB task, which is a cognitive task with a substantial motor 
component, and a more complex cognitive task of serial subtractions. My data 
show that during DT dopaminergic medication had no significant effect on straight 
walking or on turning parameters assessed with IMUs. During single tasking, only 
gait velocity was improved by the medication for straight walking. Step duration 
and peak velocity parameters improved during the turning phase. An additional 
finding was the positive effect of dopaminergic medication on CB during ST and 
DT, but not SS. 
My findings suggest that dopaminergic medication has no significant effect on 
straight walking and turning during the more daily relevant DT conditions. These 
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findings call for alternative treatment strategies and different methods of 
management. They also shed light on the positive effect of the dopaminergic 
medication on cognitive tasks with (relatively simple) motor components, rather 
than on complex tasks. This is important when targeting certain disabilities in PD 
patients to know what functions can be improved using dopaminergic medication. 
  
 58 
7. Deutsche Zusammenfassung 
 
Das idiopathische Parkinson-Syndrom (IPS) ist eine neurodegenerative 
Erkrankung, die mit der Beeinträchtigung von Motorik, Kognition und Verhalten 
einhergeht. Die Krankheit führt zu einer zunehmenden Degeneration von 
Dopamin-ausschüttenden Neuronen in den Basalganglien, welche in der Regel 
durch dopaminerge Medikamente behandelt wird. 
Dopaminerge Medikation hat verschiedene Effekte auf die unterschiedlichen 
Symptome des IPS. Sie verbessert verschiedene motorische und kognitive 
Funktionen, wie zum Beispiel Bewegungsabläufe, kognitive Flexibilität und 
Aufmerksamkeit. Jedoch hat die Medikation auf andere Bereiche, wie Gang und 
Drehbewegungen, keine positiven Effekte und kann auf bestimmte kognitive 
Prozesse sogar negativ einwirken.  
Beim hier untersuchten Geradeausgehen und Drehen, zwei gewöhnlichen 
Komponenten beim Gehen im Alltag, die von besonderem Interesse bei 
Parkinsonpatienten sind, hat die Medikation einen positiven Einfluss auf einige 
Gangparameter wie zum Beispiel Ganggeschwindigkeit. Sie hat jedoch keinen 
Effekt in anderen Bereichen wie Variabilität und Rhythmus. Anders als in den 
meisten Studien wird das Gangbild hier nicht nur unter Single Task (ST) 
Bedingungen, sondern auch unter Dual Task (DT) Bedingungen untersucht. Dies 
bildet den Alltag der Parkinsonpatienten deutlich besser ab, da sie während ihrer 
alltäglichen Aktivitäten oft mindestens zwei Aufgaben gleichzeitig durchführen. 
Daher werden in dieser Studie die Effekte dopaminerger Medikation bei 
Personen mit Parkinson auf das Geradeausgehen und Drehen unter ST und DT 
Bedingungen untersucht.  
Als DT wurden zwei sekundäre Aufgaben verwendet, eine Ankreuzaufgabe, 
welche eine motorische Komponente beinhaltet und eine komplexere kognitive 
Aufgabe, bei der die Probanden fortlaufend subtrahieren. Die Daten zeigen, dass 
die dopaminerge Medikation bei der DT Bedingung keinerlei Einfluss auf die 
untersuchten Parameter beim Gehen und Drehen hatte. Während der ST 
Bedingung konnte nur die Ganggeschwindigkeit durch die Medikation erhöht 
werden. Beim Drehen wurden die Schrittzeit und die maximale Geschwindigkeit 
verbessert. Zusätzlich hatte die Medikation einen positiven Einfluss auf die 
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Schnelligkeit der Ankreuzaufgabe, jedoch nicht auf die Schnelligkeit der 
Subtraktionsaufgabe. Unsere Ergebnisse weisen darauf hin, dass dopaminerge 
Medikation keinen signifikanten Effekt auf das Geradeausgehen und Drehen bei 
alltagsrelevanten DT Aufgaben hat. Dieses Ergebnis betont die Bedeutung von 
alternativen Behandlungsstrategien und eines alternativen 
Behandlungsmanagements. Zudem ist der positive Effekt der Medikation auf 
kognitive Aufgaben mit motorischer Komponente hervorzuheben, der im 
Gegensatz zum fehlenden Effekt der Medikation auf komplexere, forderndere 
kognitive Aufgaben steht. Diese Erkenntnisse sind wichtig um 
Funktionseinschränkungen der Parkinsonpatienten gezielt zu behandeln, mit 
dem Wissen welche Bereiche durch die dopaminerge Medikation positiv 
beeinflusst werden können. 
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9. Supplementary Materials 
A: 
 
 
 
 
 
 
 
 
 
 
  
function trenddata (f) 
   
% Make sure all your paths are correct.  
  
%Please add a list of your files names. don't forget the ' '. They have to 
%be coloured purple.  
  
subjectList = { 
    '3008on' 
   '3008off' 
    } 
  
%The next line to automatically count the number of your subjects from the 
%list you added above. NO NEED TO EDIT THIS. 
nSubjects = length(subjectList) 
  
%This line is to create a matrix. Raws are subjects, coulmns are values you 
%wil get later from the csv files. 
  
mybigmatrix = zeros(nSubjects,128); 
  
%This loop runs through everysubject, fitch it's csv file, takes the values 
%you want, organize it in only one line for each subjects and put subjects 
%in one table and finally export the table in a csv file.  
  
for i=1:nSubjects 
     
    try 
         
        subjectDir = subjectList{i} 
         
myFiles = dir(['..' filesep 'converted' filesep 'PDgait' filesep subjectDir 
filesep '13' filesep '*.csv']) 
csvPath = ['..' filesep 'converted' filesep 'PDgait' filesep subjectDir filesep 
'13' filesep myFiles(1).name] 
         
       mydata = csvread(csvPath,13,1);      
         
        %select the lines and columns you want from the matrix. (Lines are 
        %parameters, columns contain data you will use in statistics). 
        myspecific = mydata([1:end],[5:6]); 
         
        %Convert the new matrix into a vector so it's showed as one raw in you 
        %excel table. make sure the numbers fit with those in the previous 
        %line.  
        myraw = reshape(myspecific,1,128); 
         
        %UPDAED: The next few lines are to make the organisation of your 
        %values more consistent with the csv files. it goes 
        %(mean,cov,mean,cov) instead of (mean,mean,mean,cov,cov,cov). 
        %Please edit the numbers 64,128 depending on the number of 
        %parameters you are extracting. 
        meansraw = myraw(1:64) 
        covsraw = myraw(65:end) 
     
        organisedraw = zeros(1,128) 
        organisedraw(1:2:end)= meansraw 
        organisedraw(2:2:end)= covsraw 
  
         
        %creat a grand matrix where all files are add in a form of one raw per 
        %subject 
         
        mybigmatrix(i,:)= organisedraw; 
         
         
    end 
end 
  
%Creat a new csv file. Please edit the path according to your device.  
  
csvwrite('/Users/donmarat/Desktop/MD/PDgait_on&off.csv',mybigmatrix) 
  
  
end 
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B: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Material 1: 
 A: A short MATLAB function written to navigate the Mobility Lab export CSV file, fetch the specific 
data needed and generate a table with data from all study participants. Please note, this script is 
compatible with the Mobility Lab version used at the time of the analysis, 2016. 
B: A MATLAB function written to navigate the Mobility Lab export CSV file and fetch the variability 
measures of a certain parameters from individual steps in a specific step count. This function can 
be used for any gait parameter available in the Mobility lab CSV file export as long as data of 
each step is available in the file. 
 
  
function E = CalculateVariabilityMLAB 
  
%load your files, CHECK PATH 
F = dir ('iwalks/*.csv') 
  
% Replace the 153 with the number of files you have in the directory. 
for K = 1:153 
  
    FileName = ['iwalks/' F(K).name]; 
  
    %The 31 here is the row number (which gait parameter). 
    % The 9 is where the individual steps start. 
    R = csvread(FileName,31,9); 
  
    %The 40 because most patients have 40, many don't reach . 
    RR = R(1:1,1:40); 
     
    M(K, 1:40) = RR 
     
  
    clear RR; 
end 
  
csvwrite('CalculateVariability.csv', M) 
  
end 
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